StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a report published on Friday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Stock Performance
Shares of Evoke Pharma stock opened at $1.16 on Friday. The firm has a market capitalization of $3.87 million, a P/E ratio of -0.49 and a beta of 0.37. Evoke Pharma has a 52 week low of $0.92 and a 52 week high of $5.96. The company has a quick ratio of 4.04, a current ratio of 4.29 and a debt-to-equity ratio of 9.29. The firm’s 50 day moving average is $1.38 and its two-hundred day moving average is $1.80.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last announced its earnings results on Thursday, August 10th. The specialty pharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter. The business had revenue of $1.13 million for the quarter. Evoke Pharma had a negative return on equity of 258.20% and a negative net margin of 222.13%.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Further Reading
- Five stocks we like better than Evoke Pharma
- How to Invest in Cybersecurity
- 2 Recession-Proof Intelligence Stocks to Defend Your Portfolio
- How to Invest in Semiconductors
- 5 Reasons Mullen Automotive is About to Turn a Corner
- What is a Death Cross in Stocks?
- Qualcomm and Apple Forge Ahead with New Modem Partnership
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
